百濟神州(06160.HK)與維立志博達成抗LAG-3抗體LBL-007全球授權和合作協定 將獲得中國境外獨家商業化授權
格隆匯12月14日丨百濟神州(06160.HK)於2021年12月13日(美國東部時間)與南京維立志博生物科技有限公司(Nanjing Leads Biolabs Co., Ltd.,簡稱維立志博,一家立足中美的臨牀階段的私營生物科技公司)共同宣佈達成一項授權和合作協定,授予百濟神州LBL-007的全球研發和生產許可,以及中國境外的獨家商業化權利。LBL-007是一款靶向LAG-3通路的新型抗體。LBL-007用於晚期實體瘤患者的1期臨牀試驗資料已經在美國臨牀腫瘤學會(ASCO)2021年會上公佈。
百濟神州全球研發負責人汪來博士表示:“我們對於在百濟神州的產品管線中增加抗LAG-3藥物的戰略機遇以及加速LBL-007的臨牀開發並拓展對抗LAG-3通路的科學理解感到非常興奮。LBL-007在單藥治療和與其他百濟神州產品管線中的腫瘤免疫藥物聯合上都具有令人期待的組合潛力,其中包括與我們自主研發的抗PD-1抗體藥物替雷利珠單抗的聯合,以提高抗腫瘤活性。南京維立志博開發的這款臨牀候選藥物前景廣闊,不僅豐富了我們的腫瘤免疫治療藥物管線,也為我們全球臨牀研發的戰略要務和發展機遇提供了有力支持,有助於解決全球尚未被滿足的醫療需求。”
根據協定條款,維立志博將獲得3000萬美元首付款,並在達成臨牀開發、藥政批准和銷售里程碑事件後,有資格獲得至多7.42億美元的總交易額款項,及在授權地區的兩位元數分級銷售特許使用費。
維立志博CEO兼董事長康小強博士、醫學博士表示:“通過合作進一步開發LBL007是我們的一項關鍵戰略要務,我們非常高興與腫瘤領域全球領先的企業百濟神州開展合作。百濟神州是維立志博理想的合作伙伴,因為他們在全球腫瘤藥物研發方面擁有豐富的經驗,並且他們的產品管線中,還有令人矚目的腫瘤免疫治療藥物組合機會,與百濟神州結成合作夥伴將大大加速LBL-007的研發和商業化進程。”
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.